OpenAI acquires AI drug development platform
Becker's Hospital Review
OpenAI acquired Orchestra Bio, a drug development platform, to pair with its Rosalind life sciences AI. Its agents flag how a failed batch can delay a trial.
Also carried by Interesting Engineering.
This report was first published by Becker's Hospital Review. What you see here is a brief excerpt. The full text is theirs.
Continue reading at Becker's Hospital Review



